PACB vs. EYPT, QTRX, NAUT, LAB, AKYA, CTKB, HBIO, SEER, ALEC, and STTK
Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include EyePoint Pharmaceuticals (EYPT), Quanterix (QTRX), Nautilus Biotechnology (NAUT), Standard BioTools (LAB), Akoya Biosciences (AKYA), Cytek Biosciences (CTKB), Harvard Bioscience (HBIO), Seer (SEER), Alector (ALEC), and Shattuck Labs (STTK).
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.
EyePoint Pharmaceuticals has higher earnings, but lower revenue than Pacific Biosciences of California. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
EyePoint Pharmaceuticals has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. 13.1% of EyePoint Pharmaceuticals shares are owned by insiders. Comparatively, 1.4% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Pacific Biosciences of California has a net margin of -148.13% compared to Pacific Biosciences of California's net margin of -157.77%. EyePoint Pharmaceuticals' return on equity of -40.26% beat Pacific Biosciences of California's return on equity.
EyePoint Pharmaceuticals presently has a consensus price target of $33.71, indicating a potential upside of 159.54%. Pacific Biosciences of California has a consensus price target of $6.59, indicating a potential upside of 210.89%. Given EyePoint Pharmaceuticals' higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than EyePoint Pharmaceuticals.
In the previous week, EyePoint Pharmaceuticals had 5 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 32 mentions for EyePoint Pharmaceuticals and 27 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.37 beat EyePoint Pharmaceuticals' score of 0.30 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media.
EyePoint Pharmaceuticals received 6 more outperform votes than Pacific Biosciences of California when rated by MarketBeat users. Likewise, 69.81% of users gave EyePoint Pharmaceuticals an outperform vote while only 67.32% of users gave Pacific Biosciences of California an outperform vote.
Summary
EyePoint Pharmaceuticals and Pacific Biosciences of California tied by winning 9 of the 18 factors compared between the two stocks.
Get Pacific Biosciences of California News Delivered to You Automatically
Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacific Biosciences of California Competitors List
Related Companies and Tools
